The annual maintenance fee after the third year of an agreement.

No definition available.

Name:	gnpx_AnnualMaintenanceFeeAfterYearThreeAmount
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of annual maintenance fees for the first three years of an agreement.

+ References

No definition available.

+ Details

Name:	gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The minimum amount of royalty payment to be received each year.

+ References

No definition available.

+ Details

Name:	gnpx_AnnualRoyaltyPaymentPerYearMinimum
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the total amount of clinical and regulatory expense.

+ References

No definition available.

+ Details

Name:	gnpx_ClinicalAndRegulatoryExpense
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The additional amount from the commercial sales milestone payments through the FDA regulatory approval.

+ References

No definition available.

+ Details

Name:	gnpx_CommercialSalesMilestoneAdditionalFdaRegulatoryApproval
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Annual increase in contingent payment.

+ References

No definition available.

+ Details

Name:	gnpx_ContingentPaymentsAnnualIncrease
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The value of contract payments incurred and paid.

+ References

No definition available.

+ Details

Name:	gnpx_ContractPaymentsIncurredAndPaid
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Disclosure of milestone payments made for License Agreements.

+ References

No definition available.

+ Details

Name:	gnpx_LicenseAgreementMilestonePayment
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of the agreed upon licensing fee.

+ References

No definition available.

+ Details

Name:	gnpx_LicensingFeeAmount
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of annual licensing fees.

+ References

No definition available.

+ Details

Name:	gnpx_LicensingFeeAmountAnnualFirstTwoYears
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of annual licensing fees.

+ References

No definition available.

+ Details

Name:	gnpx_LicensingFeeAmountAnnualFourthAndSubsequentYears
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of annual licensing fee.

+ References

No definition available.

+ Details

Name:	gnpx_LicensingFeeAmountAnnualThirdYear
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of the management licensing fee.

+ References

No definition available.

+ Details

Name:	gnpx_LicensingFeeAmountManagement
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of the staggered upfront licensing fee.

+ References

No definition available.

+ Details

Name:	gnpx_LicensingFeeAmountStaggeredUpfront
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Estimated total cost of of long term contract.

+ References

No definition available.

+ Details

Name:	gnpx_LongTermContractEstimatedCost
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The quarterly budget allocated to long term contracts.

+ References

No definition available.

+ Details

Name:	gnpx_LongTermContractQuarterlyBudgetAllocated
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of a payment to be received upon achievement of an agreed upon milestone.

+ References

No definition available.

+ Details

Name:	gnpx_MilestonePayment
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The minimum fixed amount related to the annual royalties.

+ References

No definition available.

+ Details

Name:	gnpx_MinimumAnnualRoyaltyFixedAmountFirstTwoYears
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The fixed minimum annual amount related to the royalties.

+ References

No definition available.

+ Details

Name:	gnpx_MinimumAnnualRoyaltyFixedAmountThirdYearAndThereafter
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of sales of royalty.

+ References

No definition available.

+ Details

Name:	gnpx_RoyaltyOnSalesPercentage
Namespace Prefix:	gnpx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Minimum of annual royalty payment.

+ References

No definition available.

+ Details

Name:	gnpx_RoyaltyPaymentAnnualMinimum
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percent of net sales of licensed technology covered by patents to be earned as royalty.

+ References

No definition available.

+ Details

Name:	gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent
Namespace Prefix:	gnpx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Terms of the royalty agreement, as a percentage of net sales of licensed technologies .

+ References

No definition available.

+ Details

Name:	gnpx_RoyaltyTerms
Namespace Prefix:	gnpx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement.

+ References

No definition available.

+ Details

Name:	gnpx_ShareOfNonroyaltySublicenseIncomePercent
Namespace Prefix:	gnpx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Subparagraph (ee)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-17

+ Details

Name:	us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gnpx_NationalInstituteOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gnpx_ResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gnpx_MdAndersonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gnpx_NyuMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gnpx_UniversityOfMichiganMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gnpx_UniversityOfPittsburghMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=gnpx_RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gnpx_UthealthHoustonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)			1 Months Ended		3 Months Ended			5 Months Ended	12 Months Ended
	May 02, 2025	Sep. 30, 2022	Jun. 30, 2024	Jul. 31, 2018	Mar. 31, 2026	Mar. 31, 2025	Mar. 31, 2017	Jun. 06, 2024	Dec. 31, 2024	Dec. 31, 2009	Dec. 31, 2025	Apr. 25, 2025	Feb. 17, 2025	Nov. 11, 2024	Mar. 03, 2021
Costs and Expenses					$ 4,494,184	$ 3,969,292
License Agreement Terms [Member]
License Agreement Milestone Payment															$ 6,150,000
National Institute of Health [Member]
Costs and Expenses					0	0
Contract Payments Incurred and Paid					525,000
Royalty on Sales, Percentage										1.00%
Royalty Term (Year)										21 years
Royalty Payment, Annual Minimum										$ 20,000
Payment for Contingent Consideration Liability, Operating Activities							$ 240,000
Contingent Payments Annual Increase							$ 20,000
Other Commitment					420,000						$ 400,000
Research Agreement [Member] \| MD Anderson [Member]
Long Term Contract, Estimated Cost		$ 2,900,000		$ 2,000,000				$ 2,900,000	$ 2,760,000
Long Term Contract, Quarterly Budget Allocated			$ 165,000					$ 240,000
Costs and Expenses					165,701
Contract Payments Incurred and Paid					2,600,000
License Agreement [Member] \| NYU [Member]
Costs and Expenses					0
Contract Payments Incurred and Paid					5,000
Licensing Fee, Amount												$ 5,000
Licensing Fee, Amount, Annual, First Two Years												35,000
Licensing Fee, Amount, Annual, Third Year												25,000
Licensing Fee, Amount, Annual, Fourth and Subsequent Years												50,000
Milestone Payment												$ 400,000
License Agreement [Member] \| NYU [Member] \| Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent												1.00%
License Agreement [Member] \| NYU [Member] \| Maximum [Member]
Royalty Percent, Licensed Technology Covered by Patent												2.00%
License Agreement [Member] \| University Of Michigan [Member]
Costs and Expenses					15,000	15,000
Contract Payments Incurred and Paid					30,000
Licensing Fee, Amount														$ 30,000
Minimum Annual Royalty Fixed Amount, First Two Years														15,000
Minimum Annual Royalty Fixed Amount, Third Year and Thereafter														30,000
Commercial Sales Milestone, Additional FDA Regulatory Approval														$ 350,000
License Agreement [Member] \| University Of Michigan [Member] \| Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent														1.00%
Share of Non-Royalty Sublicense Income, Percent														10.00%
License Agreement [Member] \| University Of Michigan [Member] \| Maximum [Member]
Royalty Percent, Licensed Technology Covered by Patent														3.00%
Share of Non-Royalty Sublicense Income, Percent														40.00%
License Agreement [Member] \| University of Pittsburgh [Member]
Costs and Expenses					65,000	$ 10,000
Contract Payments Incurred and Paid					75,000
Licensing Fee, Amount													$ 10,000
Annual Maintenance Fee, First Three Years, Amount													65,000
Annual Maintenance Fee, After Year Three, Amount													120,000
License Agreement [Member] \| University of Pittsburgh [Member] \| Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Licensing Fee, Amount	$ 10,000
Milestone Payment													$ 4,825,000
Share of Non-Royalty Sublicense Income, Percent													20.00%
Annual Royalty Payment Per Year, Minimum													$ 250,000
License Agreement [Member] \| University of Pittsburgh [Member] \| Minimum [Member] \| Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent													1.50%
License Agreement [Member] \| University of Pittsburgh [Member] \| Maximum [Member] \| Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member]
Royalty Percent, Licensed Technology Covered by Patent													3.00%
License Agreement [Member] \| UTHealth Houston [Member]
Contract Payments Incurred and Paid					$ 20,000
Annual Royalty Payment Per Year, Minimum	25,000
Licensing Fee, Amount, Staggered Upfront	40,000
Licensing Fee, Amount, Management	3,000
Clinical and Regulatory Expense	$ 360,000
License Agreement [Member] \| UTHealth Houston [Member] \| Minimum [Member]
Royalty Percent, Licensed Technology Covered by Patent	0.10%
License Agreement [Member] \| UTHealth Houston [Member] \| Maximum [Member]
Royalty Percent, Licensed Technology Covered by Patent	0.25%